Literature DB >> 30876658

Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial).

Ravi B Patel1, Muthiah Vaduganathan2, G Michael Felker3, Javed Butler4, Margaret M Redfield5, Sanjiv J Shah6.   

Abstract

Although atrial fibrillation/atrial flutter (AF/AFL) and heart failure with preserved ejection fraction (HFpEF) frequently coexist, the influence of AF/AFL on physical activity, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and quality of life in HFpEF is unclear and could have relevance to HFpEF trial design. We evaluated the association between AF/AFL and volitional physical activity, functional performance, NT-proBNP, and quality of life in patients with HFpEF in the Nitrate's Effect on Activity Tolerance (NEAT)-HFpEF trial. Of 99 patients with accelerometer data, 35 (35%) had AF/AFL. There were no differences between AF/AFL versus no AF/AFL in baseline average daily accelerometer units (ADAUs; 9.06 ± 0.54 vs 9.06 ± 0.48, p = 0.75), hours active per day (9.7 ± 2.3 vs 9.2 ± 2.2, p = 0.86), or 6-minute walk distance (6MWD; 307 ± 136m vs 321 ± 110m, p = 0.85). AF/AFL status was associated with higher baseline NT-proBNP (586 [25th to 75th percentile: 291 to 1254] pg/ml vs 154 [25th to 75th percentile: 92 to 288] pg/ml, p <0.001) and Kansas City Cardiomyopathy Questionnaire scores (69 [25th to 75th percentile: 46 to 88] vs 48 [25th to 75th percentile: 37 to 70], p = 0.01). Although treatment responses to isosorbide mononitrate measured by change in ADAUs, hours active per day, or 6MWD did not vary by AF/AFL status (interaction p >0.05 for all), AF/AFL patients had greater reductions in NT-proBNP after isosorbide mononitrate than patients without AF/AFL (interaction p <0.001), possibly due to regression to the mean. In conclusion, baseline measures and treatment-related changes in volitional physical activity (ADAUs) and functional performance (6MWD) did not differ by AF/AFL in NEAT-HFpEF, whereas NT-proBNP did. In HFpEF-where AF/AFL prevalence is high-functional measures may be superior to natriuretic peptides as trial endpoints.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30876658      PMCID: PMC6488421          DOI: 10.1016/j.amjcard.2019.02.025

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  2 in total

1.  Day-to-day Relationships between Physical Activity and Sleep Characteristics among People with Heart Failure and Insomnia.

Authors:  Garrett Ash; Sangchoon Jeon; Samantha Conley; Andrea K Knies; Henry K Yaggi; Daniel Jacoby; Christopher S Hollenbeak; Sarah Linsky; Meghan O'Connell; Nancy S Redeker
Journal:  Behav Sleep Med       Date:  2020-10-13       Impact factor: 3.492

2.  Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction.

Authors:  Sanjiv J Shah; Martin R Cowie; Rolf Wachter; Peter Szecsödy; Victor Shi; Ghionul Ibram; Mo Hu; Ziqiang Zhao; Jianjian Gong; Burkert Pieske
Journal:  Eur J Heart Fail       Date:  2021-07-26       Impact factor: 17.349

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.